American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals?

by admin December 18, 2024
December 18, 2024
TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals?

Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn’s disease, two of the most prevalent forms of inflammatory bowel disease (IBD).

The announcement, which sent Teva’s stock soaring by 26.4% to $20.88 and Sanofi’s up 6.7% to $48.94, marks a significant milestone in IBD treatment development.

Promising trial results drive optimism

The trials revealed strong efficacy in treating both conditions. In ulcerative colitis patients, 36.2% of those receiving a low dose and 47.8% in the high-dose group achieved clinical remission compared to just 20.5% of the placebo group.

Among Crohn’s disease patients, 26.1% in the low-dose group and 47.8% in the high-dose group demonstrated endoscopic responses, compared to only 13% in the placebo group.

Sanofi’s head of research and development, Houman Ashrafian, described the results as “unprecedented.”

He highlighted duvakitug’s potential as a breakthrough treatment for IBD, saying,

If the magnitude of effect persists in the Phase 3 program, we believe we will have a differentiated medicine for patients who are in urgent need of new options.

The TL1A frontier

Duvakitug targets TL1A, a protein implicated in a variety of immunologic diseases.

While the initial focus is on gastrointestinal conditions like ulcerative colitis and Crohn’s disease, experts suggest duvakitug could eventually treat conditions such as arthritis and skin or lung diseases.

Teva CEO Richard Francis previously described duvakitug as a “multibillion-dollar blockbuster.”

The TL1A class has attracted significant interest, with companies like Merck (MRK) and Roche (RHHBY) investing billions to develop their own TL1A-targeting drugs.

Teva and Sanofi’s drug appears to outperform rivals in placebo-adjusted responses.

Evercore ISI analyst Umer Raffat noted Teva’s efficacy surpassed Merck’s by 16% to 27% and Roche’s by 18% to 23%.

Challenges and competition remain

Despite the promising results, Teva and Sanofi face a competitive landscape. Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7.1 billion deal to acquire Televant underscore the high stakes in this therapeutic area.

Piper Sandler analyst Christopher Raymond predicts that AbbVie’s (ABBV) Skyrizi and Rinvoq will continue gaining traction in the IBD space, even as TL1A therapies like duvakitug advance.

Safety profile and next steps

Duvakitug was well-tolerated in trials, with no new safety concerns reported, further boosting confidence in its potential.

Teva and Sanofi now face the critical Phase 3 trials, which will determine whether the drug can sustain its efficacy and safety profile.

The TL1A space is still in its infancy, but Teva and Sanofi’s strong trial results could position duvakitug as a frontrunner in the race to develop innovative treatments for IBD and related conditions.

Market impact and investor sentiment

Teva’s stock hit its highest level since December 2018, reflecting investor optimism.

Analysts like Raffat remain bullish, with outperform ratings citing the drug’s “best-in-class” efficacy.

With a growing portfolio in immunology and the potential to expand into other autoimmune conditions, Teva and Sanofi are poised to reshape the treatment landscape for inflammatory diseases.

The post TEVA stock soars 26%: What’s going on with Teva Pharmaceuticals? appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Tata Motors shares crash 3% on Wednesday: technical analysts warn of possible dip below ₹700
next post
Here’s why the Bovespa Index and Brazilian real are plunging

Related Posts

Tata Motors, SBI, and 3 more large-cap stocks...

January 2, 2025

Next joins £1 billion profit club as sales...

March 27, 2025

Avoid Mullen Automotive and VinFast; buy this EV...

October 29, 2024

Constellation Energy stock surged: brace for a pullback

September 23, 2024

Pop Mart shares slide despite rosy profit outlook:...

July 16, 2025

Fatburger parent company, chairman charged in alleged fraud...

May 14, 2024

Netflix vs movie theaters: is the streaming giant...

December 28, 2024

Five ETFs to invest in to hedge against...

February 9, 2025

JEPI forecast: will this covered call ETF rise...

January 6, 2025

Middle East set to overtake Asia to become...

July 15, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • How Donald Trump’s immigration crackdown may tank the labor market

      August 4, 2025
    • Trump’s tariff threat looms over India’s Russian oil deals

      August 4, 2025
    • Trump moves nuclear submarines near Russia: what triggered the move and what’s ahead

      August 3, 2025
    • BOE rate cuts offer little relief as UK households face mounting financial strain

      August 3, 2025
    • Retail investors shift focus to Europe as US valuations stretch

      August 3, 2025

    Categories

    • Business (3,583)
    • Investing (2,703)
    • Latest News (2,031)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved